Complementary new approaches enable repositioning of failed drug candidates - PubMed (original) (raw)

Editorial

Complementary new approaches enable repositioning of failed drug candidates

Louis A Tartaglia. Expert Opin Investig Drugs. 2006 Nov.

Abstract

Until recently, safe drug candidates that failed in clinical trials were shelved as drug developers channelled resources to the next candidates in the pipeline. In the past few years, new technologies, improved genomic information and high-throughput methods have made it possible to quickly and economically re-examine advanced drug candidates for therapeutic activity against other diseases. This development arrives at an opportune time, as pharmaceutical companies strive to fill sparse late-stage pipelines at the same time as keeping costs down. Specialised companies are emerging with new methods and a fresh point of view to assist pharmaceutical developers in turning failed drug candidates from one therapeutic area into successful treatments in another. This editorial introduces a series of papers to be published in Expert Opinion on Investigational Drugs, discussing discontinued drugs from 2005.

PubMed Disclaimer

Similar articles

• Scale and scope in drug development: unpacking the advantages of size in pharmaceutical research.
  Cockburn IM, Henderson RM. Cockburn IM, et al. J Health Econ. 2001 Nov;20(6):1033-57. doi: 10.1016/s0167-6296(01)00108-4. J Health Econ. 2001. PMID: 11758047
• Costing drug development.
  [No authors listed] [No authors listed] Nat Rev Drug Discov. 2003 Apr;2(4):247. doi: 10.1038/nrd1070. Nat Rev Drug Discov. 2003. PMID: 12680358 No abstract available.
• New estimates of drug development costs.
  Frank RG. Frank RG. J Health Econ. 2003 Mar;22(2):325-30. doi: 10.1016/S0167-6296(03)00002-X. J Health Econ. 2003. PMID: 12606149 No abstract available.
• Trends in risks associated with new drug development: success rates for investigational drugs.
  DiMasi JA, Feldman L, Seckler A, Wilson A. DiMasi JA, et al. Clin Pharmacol Ther. 2010 Mar;87(3):272-7. doi: 10.1038/clpt.2009.295. Epub 2010 Feb 3. Clin Pharmacol Ther. 2010. PMID: 20130567 Review.
• The antibiotic pipeline: reviving research and development and speeding drugs to market.
  Luepke KH, Mohr JF 3rd. Luepke KH, et al. Expert Rev Anti Infect Ther. 2017 May;15(5):425-433. doi: 10.1080/14787210.2017.1308251. Epub 2017 Mar 29. Expert Rev Anti Infect Ther. 2017. PMID: 28306360 Review.

Cited by

• Drug repositioning as a route to anti-malarial drug discovery: preliminary investigation of the in vitro anti-malarial efficacy of emetine dihydrochloride hydrate.
  Matthews H, Usman-Idris M, Khan F, Read M, Nirmalan N. Matthews H, et al. Malar J. 2013 Oct 9;12:359. doi: 10.1186/1475-2875-12-359. Malar J. 2013. PMID: 24107123 Free PMC article.
• Repurposing INCI-registered compounds as skin prebiotics for probiotic Staphylococcus epidermidis against UV-B.
  Balasubramaniam A, Adi P, Tra My DT, Keshari S, Sankar R, Chen CL, Huang CM. Balasubramaniam A, et al. Sci Rep. 2020 Dec 9;10(1):21585. doi: 10.1038/s41598-020-78132-5. Sci Rep. 2020. PMID: 33299009 Free PMC article.
• Epidrug Repurposing: Discovering New Faces of Old Acquaintances in Cancer Therapy.
  Montalvo-Casimiro M, González-Barrios R, Meraz-Rodriguez MA, Juárez-González VT, Arriaga-Canon C, Herrera LA. Montalvo-Casimiro M, et al. Front Oncol. 2020 Nov 18;10:605386. doi: 10.3389/fonc.2020.605386. eCollection 2020. Front Oncol. 2020. PMID: 33312959 Free PMC article. Review.
• Drug repurposing: a systematic review on root causes, barriers and facilitators.
  Krishnamurthy N, Grimshaw AA, Axson SA, Choe SH, Miller JE. Krishnamurthy N, et al. BMC Health Serv Res. 2022 Jul 29;22(1):970. doi: 10.1186/s12913-022-08272-z. BMC Health Serv Res. 2022. PMID: 35906687 Free PMC article.
• Three-Dimensional Cell Metabolomics Deciphers the Anti-Angiogenic Properties of the Radioprotectant Amifostine.
  Katsila T, Chasapi SA, Gomez Tamayo JC, Chalikiopoulou C, Siapi E, Moros G, Zoumpoulakis P, Spyroulias GA, Kardamakis D. Katsila T, et al. Cancers (Basel). 2021 Jun 9;13(12):2877. doi: 10.3390/cancers13122877. Cancers (Basel). 2021. PMID: 34207535 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon

• Other Literature Sources

  • The Lens - Patent Citations Database

• Miscellaneous

  • NCI CPTAC Assay Portal